Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006-2015, an Analysis of the SEER Registry
- PMID: 32208196
- DOI: 10.1016/j.jss.2020.02.010
Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006-2015, an Analysis of the SEER Registry
Abstract
Background: Acral lentiginous melanoma (ALM) is one of the four major subtypes in cutaneous malignant melanoma (CMM). We aimed to study the incidence and survival of ALM in the United States in recent 10 y and compare the survival between ALM and nonacral CMM. In the meantime, racial disparity and prognostic factors associated with survival were investigated.
Methods: All the cases of ALM registered in the Surveillance, Epidemiology, and End Results registry from 2006 to 2015 were retrieved, including non-Hispanic whites (NHW), black Americans (blacks), Asian/Pacific Islanders, and Hispanic whites. Age-adjusted incidence was calculated. Clinicopathologic data, including age, gender, race, geographic location, Breslow thickness, ulceration, pathologic staging, sentinel lymph node status, and surgical approach, were collected and analyzed. Melanoma-specific survival (MSS) was analyzed in patients with ALM and CMM. The Kaplan-Meier method was used to estimate the influence of clinicopathologic data on ALM MSS. Only cases with complete staging and active follow-up were included in prognostic factor analysis.
Results: A total of 1724 ALM and 87,442 nonacral CMM patients were included in the study. For ALM patients, the age-adjusted incidence rate was 2.0 per million person-years. The proportion of ALM among all melanoma subtypes was greatest in blacks (32.6%). The 5-y MSS rates of ALM were lower than CMM overall (80.6% versus 93.0%, P < 0.001, respectively). When controlled by stage, the difference was significant in patients diagnosed at stages I and III. ALM 5-y MSS rates were highest (84.3%) in NHW, intermediate in Asian/Pacific Islanders (76.6%), Hispanic white (72.0%), and lowest in blacks (66.9%). Blacks were elderly, male predominant, located in East and Middle American, and had thicker, more ulcerated, advanced disease as compared with NHWs. When controlled by stage, survival difference was significant between NHWs and blacks in stage I (P = 0.004) and stage III (P = 0.005) patients. Gender, race, sentinel lymph node status, and pathologic stage were identified as independent risk factors in multivariate analysis.
Conclusions: The incidence of ALM has been steady in recent 10 y and more prevalent in aged people. ALM is associated with a worse prognosis than CMM. Black Americans have the worst prognosis, and survival difference is significant between NHW and blacks.
Keywords: Acral lentiginous melanoma; Cutaneous melanoma; Racial disparity; Survival.
Copyright © 2020. Published by Elsevier Inc.
Similar articles
-
Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.Arch Dermatol. 2009 Apr;145(4):427-34. doi: 10.1001/archdermatol.2008.609. Arch Dermatol. 2009. PMID: 19380664 Free PMC article.
-
Trends by race and ethnicity in incidence and mortality of acral lentiginous melanoma: analysis of Surveillance, Epidemiology, and End Results 2000-2020.Arch Dermatol Res. 2024 Jul 5;316(7):456. doi: 10.1007/s00403-024-03167-x. Arch Dermatol Res. 2024. PMID: 38967822
-
Racial differences in six major subtypes of melanoma: descriptive epidemiology.BMC Cancer. 2016 Aug 30;16(1):691. doi: 10.1186/s12885-016-2747-6. BMC Cancer. 2016. PMID: 27576582 Free PMC article.
-
Baseline Serum neutrophil-to-lymphocyte ratio in acral melanoma compared with nonacral melanoma and its prognostic significance.J Am Acad Dermatol. 2024 May;90(5):977-985. doi: 10.1016/j.jaad.2023.12.064. Epub 2024 Jan 23. J Am Acad Dermatol. 2024. PMID: 38272394 Review.
-
Acral Lentiginous Melanoma. Part I. Epidemiology, Etiology, Clinical Presentation, and Diagnosis.J Am Acad Dermatol. 2025 Jan 8:S0190-9622(25)00011-8. doi: 10.1016/j.jaad.2024.10.124. Online ahead of print. J Am Acad Dermatol. 2025. PMID: 39793708 Review.
Cited by
-
Management of acral lentiginous melanoma: current updates and future directions.Front Oncol. 2024 Feb 8;14:1323933. doi: 10.3389/fonc.2024.1323933. eCollection 2024. Front Oncol. 2024. PMID: 38390259 Free PMC article. Review.
-
Vigilance to misleading information is required to avoid delayed diagnosis: Case series of acral melanomas.Ann Med Surg (Lond). 2021 Apr 21;65:102270. doi: 10.1016/j.amsu.2021.102270. eCollection 2021 May. Ann Med Surg (Lond). 2021. PMID: 33996043 Free PMC article.
-
Unveiling Melanoma: A Deep Dive into Disparities at a Latin-American Cancer Institute.Ann Surg Oncol. 2024 Sep;31(9):6097-6117. doi: 10.1245/s10434-024-15573-6. Epub 2024 Jun 18. Ann Surg Oncol. 2024. PMID: 38888862
-
Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma.Pigment Cell Melanoma Res. 2025 May;38(3):e70027. doi: 10.1111/pcmr.70027. Pigment Cell Melanoma Res. 2025. PMID: 40405404 Free PMC article.
-
Comparative Analysis of Acral Melanoma in Chinese and Caucasian Patients.J Skin Cancer. 2020 Oct 6;2020:5169051. doi: 10.1155/2020/5169051. eCollection 2020. J Skin Cancer. 2020. PMID: 33083061 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical